[Photo by charliepix on Canva].
The rapid growth of GLP-1 medicines has changed the weight-management market, creating demand for clinical services that can provide treatment alongside ongoing patient support. Glasgow-based Curely has placed this category at the centre of its business, focusing particularly on prescription weight-loss medicines and a subscription-based model.
Launched around late 2023, the UK-registered and regulated online pharmacy offers Mounjaro, Wegovy and Orlistat alongside other pharmaceutical products. Its wider catalogue covers women’s health, men’s health, sexual health, travel, general health and skincare, although weight management remains the company’s main growth priority.
By late 2025, Curely reported approximately £1 million in monthly revenue, with trailing 12-month revenue of about £5 million. Daily website traffic averaged roughly 3,000 to 3,300 visitors, while July 1, 2025, brought a reported peak of 10,392 visitors.
A Focused Approach to Clinical Weight Management
Curely’s weight-loss offering centres on GLP-1 treatments, including Mounjaro and Wegovy. Mounjaro contains tirzepatide and is manufactured by Eli Lilly. It is administered weekly, with a pen typically providing a one-month supply. Wegovy contains semaglutide and is also administered by injection.
The clinical context matters because weight management is connected to wider health outcomes. John Sharretts, M.D., of the FDA Center for Drug Evaluation and Research, has said: “Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes.”
Curely supplements access to medication with information covering practical parts of treatment, including injection sites, expected timelines, possible side effects and diet. This educational role is particularly relevant for medicines that patients administer themselves over an extended period.
Research also provides context for the wider use of prescription weight-management medicines. The National Institute of Diabetes and Digestive and Kidney Diseases reports that, on average, adults taking prescription medication as part of a lifestyle programme lose 3% to 12% more of their starting body weight after one year than people following a lifestyle programme without medication.
Flexible Subscriptions Address Long-Term Treatment Needs
Curely’s commercial model is built around monthly subscriptions for weight-loss pens. Subscriptions have no tie-ins or cancellation fees. Patients can pause treatment or change dosage, subject to the appropriate clinical process.
This structure reflects the ongoing nature of weight-management treatment rather than treating each prescription as an isolated purchase. Curely combines the medication with online consultations and continuing clinical support, while free delivery is available across the UK.
Key elements of the service include:
- Private and secure online consultations
- Monthly access to prescribed weight-loss medication
- The option to pause subscriptions
- Dosage changes where clinically appropriate
- Free UK delivery
- Ongoing clinical guidance
For consumers comparing online weight-management services, Curely therefore represents a digital-first model in which consultation, prescription management, delivery and ongoing support sit within the same service.
The subscription approach also shapes the company’s economics. Curely estimates customer lifetime value for GLP-1 subscriptions at around six times a roughly £200 monthly subscription, or approximately £1,200. Its reported average order value is about £140, while its average website conversion rate is around 4%.
Pricing Targets a Cost-Conscious Market
Price is another major part of Curely’s strategy. The company describes the GLP-1 market as highly price-sensitive and has adopted aggressive pricing to attract consumers who may otherwise use larger pharmacy providers.
That approach has accompanied significant revenue growth. The business reported monthly revenue of about £1 million at its November 2025 peak, despite not relying heavily on traditional paid advertising.
Affordability is particularly relevant when treatment continues over several months. A small difference in monthly cost can become more significant across a longer course of care. Curely’s combination of pricing and subscription flexibility therefore addresses two practical concerns at once: ongoing expense and uncertainty about how long an individual may remain on treatment.
The company’s focus also reflects growing interest in medication as one part of structured weight management. A trial published in the New England Journal of Medicine concluded: “In this trial, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.”
That wording is important because the research refers to medication alongside lifestyle intervention rather than presenting treatment as a standalone solution.
Clinical Support Shapes the Digital Patient Experience
Online access can remove the need for a traditional pharmacy visit, but it also increases the importance of clinical oversight and clear patient communication. Curely positions its regulated status and pharmacist expertise as central parts of its service.
The pharmacy is listed with registration number 9012481, while its online consultations are designed to provide discreet access to prescription treatment. Curely also uses clinical experts in educational content and external commentary. The aim is to build medical authority around a service delivered primarily through digital channels.
The company reports an “Excellent” Trustpilot rating and has received coverage through publications including MSN, Forbes and Men’s Health. These signals sit alongside its focus on patient education, particularly around how GLP-1 medicines are used and what patients may experience during treatment.
Curely has also outlined plans for an AI-first platform, including chatbot technology intended to support customer service as patient numbers increase. How such technology fits alongside pharmacist-led clinical care will be an important part of the platform’s development.
From Weight Loss to Lifestyle Management
Curely’s broader positioning attempts to move discussion of GLP-1 medicines away from their association solely with severe obesity. The company instead uses the language of “lifestyle optimization,” particularly when addressing adults seeking support with weight and physical health as they age.
Its primary audience is women aged 30 to 45, within a UK market the company estimates includes around two million GLP-1 users. Curely currently serves only the UK, although its longer-term ambitions include international growth.
For now, the company remains concentrated on domestic weight management. Its reported growth, flexible subscriptions, price-focused strategy and emphasis on clinical support show how specialist online pharmacies are adapting to increasing demand for GLP-1 treatment.
Future pharmaceutical launches may broaden the options available, but Curely’s current direction remains centred on making ongoing, clinically managed weight-loss treatment accessible through a digital service.
